| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program |
| Creator | Le Du et al. |
| Author | Fanny Le Du |
| Author | Matthieu Carton |
| Author | Thomas Bachelot |
| Author | Mahasti Saghatchian |
| Author | Barbara Pistilli |
| Author | Etienne Brain |
| Author | Delphine Loirat |
| Author | Laurence Vanlemmens |
| Author | Thomas Vermeulin |
| Author | George Emile |
| Author | Mony Ung |
| Author | Marie Robert |
| Author | Isabelle Desmoulins |
| Author | Christelle Jouannaud |
| Author | Lionel Uwer |
| Author | Jean Marc Ferrero |
| Author | Marie-Ange Mouret-Reynier |
| Author | William Jacot |
| Author | Michaël Chevrot |
| Author | Suzette Delaloge |
| Abstract | BACKGROUND: Although adjuvant cancer treatments increase cure rates, they may induce clonal selection and tumor resistance. Information still lacks as whether (neo)adjuvant anti-HER2 treatments impact the patterns of recurrence and outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC). We aimed to assess this in the large multicenter ESME real-world database. PATIENTS AND METHODS: We examined the characteristics and outcomes (overall survival (OS) and progression-free survival under first-line treatment (PFS1)) of HER2+ patients with MBC from the French ESME program with recurrent disease, as a function of the previous receipt of adjuvant trastuzumab. Multivariable analyses used Cox models adjusted for baseline demographic, prognostic factors, adjuvant treatment received, and disease-free interval. RESULTS: Two thousand one hundred and forty-three patients who entered the ESME cohort between 2008 and 2017 had a recurrent HER2+ MBC. Among them, 56% had received (neo)adjuvant trastuzumab and 2.5% another anti-HER2 in this setting. Patients pre-exposed to trastuzumab were younger, had a lower disease-free interval, more HR-negative disease and more metastatic sites. While the crude median OS appeared inferior in patients exposed to adjuvant trastuzumab, as compared to those who did not (37.2 (95%CI 34.4-40.3) versus 53.5 months (95% CI: 47.6-60.1)), this difference disappeared in the multivariable model (HR = 1.05, 95%CI 0.91-1.22). The same figures were observed for PFS1. CONCLUSIONS: Among patients with relapsed HER2+ MBC, the receipt of adjuvant trastuzumab did not independently predict for worse outcomes when adjusted to other prognostic factors. |
| Publication | The Oncologist |
| Volume | 28 |
| Issue | 10 |
| Pages | e867-e876 |
| Date | 2023-10-03 |
| Journal Abbr | Oncologist |
| Language | eng |
| DOI | 10.1093/oncolo/oyad137 |
| ISSN | 1549-490X |
| Library Catalog | PubMed |
| Extra | PMID: 37589218 PMCID: PMC10546827 |
| Tags | anti-HER2-targeted agents, Antineoplastic Combined Chemotherapy Protocols, breast cancer, Breast Neoplasms, Chemotherapy, Adjuvant, clinic, de novo metastatic, Disease-Free Survival, Female, HER2 positive, Humans, pertuzumab, Progression-Free Survival, Receptor, ErbB-2, Trastuzumab |
| Date Added | 2023/10/16 - 15:02:17 |
| Date Modified | 2023/10/16 - 17:19:14 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
